Filtricine Appoints a New Chief Executive Officer
Dear friends of Filtricine,
It is our great pleasure to announce that Dr. John Chant has accepted our offer as Chief Executive Officer. John will assume the position on Dec 20, 2020.
The Board and the founder team are unanimously supportive and excited to have an industry guru with established track record to take the helm. As Filtricine’s current Strategic Advisor, John has been deeply involved in Filtricine’s operations in many avenues. His belief in Filtricine’s mission and deep understanding of Filtricine’s technology will be combined with his extensive executive experience in early stage biotech companies to lead Filtricine through the next stage of its development, and ultimately into a great venture success.
John founded and served as CEO of two successful oncology start-ups, Gatekeeper Pharmaceuticals and G1 Therapeutics (NASDAQ: GTHX), both in oncology. Prior to deciding to launch his own ventures, John gained valuable experience working at CuraGen and Genentech in a group leading roles for biotechnology and drug development. John holds a Ph.D. in Genetics from the University of California, San Francisco, and held the appointment of Associate Professor of Molecular and Cellular Biology at Harvard University for close to a decade. He has received numerous awards, and he has published widely. He has consulted for numerous venture capital firms, hedge funds, and biotechnology companies.
We are confident that Filtricine will thrive under John’s leadership.
The Filtricine team